Patients with HER2-low breast cancer are now recognized as being part of a distinct subgroup who may benefit from T-DXd, and this was affirmed in a 2023 update of the American Society of Clinical Oncology (ASCO-CAP) guidelines [6]. This evidence concerns the gene ERBB2 and breast carcinoma.